This report provides key findings from the 2022 National Survey on Drug Use and Health (NSDUH) on substance use, mental health, and treatment among the noninstitutionalized U.S. population aged 12 or older. Estimates are presented by age group and by race/ethnicity for selected measures.

Read key findings from the 2021 National Survey on Drug Use and Health (NSDUH) on substance use, mental health, and treatment. Metrics in the report cover the civilian, noninstitutionalized US population ages 12 and older. Estimates are presented by age group and by race/ethnicity for selected measures. Unlike other NSDUH Annual National Reports, the 2021 report has no discussion of trends over time, because changes in survey methodology mean the indicators are not comparable to past NSDUH estimates.

This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.

The guide provides considerations and strategies for interdisciplinary teams, peer specialists, clinicians, registered nurses, behavioral health organizations, and policy makers in understanding, selecting, and implementing evidence-based interventions that support older adults with serious mental illness.

This updated TIP reviews what is known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine, as well as the misuse of prescription stimulants. The TIP offers recommendations on treatment approaches and maximizing treatment engagement and retention, and strategies for initiating and maintaining abstinence.

This guide reviews literature on treating college students’ mental health concerns, such as anxiety, depression, and suicidal thoughts and behaviors; distills the research into recommendations for practice; and provides examples of the ways that these recommendations can be implemented.

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.